Results for numberguidelines translation from English to Portuguese

-05.06.2000 -31.07.2000 -27.10.2000 -89 days-10.05.2000 -31.07.2000 -27.10.2000 -89 days-07.08.2000 -25.08.2000 -21.11.2000 -89 days -08.08.2000 -22.09.2000 -21.11.2000 -61 days -01.09.2000 -22.09.2000 -21.11.2000 -61 days -09.08.2000 -22.09.2000 -19.12.2000 -89 days -02.05.2000 -19.10.2000 -19.12.2000 -62 days -10.08.2000 -19.10.2000 -19.12.2000 -62 days -11.08.2000 -19.10.2000 -19.12.2000 -62 days -21.08.2000 -19.10.2000 -19.12.2000 -62 days -07.08.2000 -25.08.2000 -21.11.2000 -89 days -08.09.2000 -19.10.2000 -19.12.2000 -62 days -03.10.2000 -19.10.2000 -19.12.2000 -62 days -04.10.2000 -19.10.2000 -19.12.2000 -62 days-6.11.2000 -29.12.2000-6.11.2000 -29.12.2000------------83annex 11:emea guidelines in 2000cpmp biotechnology working partyreference numberguidelines/statusemea/cpmp/bwp/840/00emea/cpmp/bwp/1244/00emea/cpmp/bwp/3326/99emea/cpmp/bwp/3354/99 draftemea/cpmp/bwp/3207/00emea/cpmp/bwp/1143/00emea/cpmp/bwp/269/95rev.2emea/cpmp/bwp/2571/00final eu recommendations for the influenza vaccine composition for the season 2000/2001 adopted april 2000 report of the emea expert workshop on human tses and plasma-derived medicinal products, 15-16 may 2000 adopted july 2000 concept paper on the development of a points to consider on xenogeneic cell therapy adopted november 2000 note for guidance on the production and quality control of animal immunoglobulins and immunosera for human use released for consultation january 2000 note for guidance on comparability of medicinal products containing biotechnology-derived proteins as active substances released for consultation may 2000 position statement on the use of tumorigenic cells of human origin for the production of biological and biotechnological medicinal products released for consultation july 2000 revision of section 3.2.5 of cpmp note for guidance on plasma-derived medicinal products released for consultation july 2000 points to consider on the reduction, elimination or substitution of thiomersal in vaccines released for consultation november 2000
emea/mb/050/00 relatório anual 2000 page 84/88 anexo 11 linhas de orientação da emea em 2000 grupo de trabalho " biotecnologia " do cpmp número de referência linhas de orientação situação final eu recommendations for the emea/cpmp/bwp/840/00 influenza vaccine composition for the aprovada em abril de 2000 season 2000/2001 report of the emea expert workshop on emea/cpmp/bwp/1244/00 human tses and plasma-derived medicinal aprovada em julho de 2000 products, 15-16 maio de 2000 concept paper on the development of a emea/cpmp/bwp/3326/99 points to consider on xenogeneic cell aprovada em novembro de 2000 therapy note for guidance on the production and emea/cpmp/bwp/3354/99 publicado para consulta em janeiro quality control of animal immunoglobulins draft de 2000 and immunosera for human use note for guidance on comparability of medicinal products containing publicado para consulta em maio de emea/cpmp/bwp/3207/00 biotechnology-derived proteins as active 2000 substances position statement on the use of tumorigenic cells of human origin for the publicado para consulta em julho de emea/cpmp/bwp/1143/00 production of biological and 2000 biotechnological medicinal products revision of section 3. 2. 5 of cpmp note emea/cpmp/bwp/269/95 publicado para consulta em julho de for guidance on plasma-derived medicinal rev.